Send a Message
to trendor45

Comments

71

Joined

Sep 23, 2013

trendor45 Profile

Forums Owned

Recent Posts

US News

Polypore (PPO) Settlement, License Agreement, Up-front Pa...

Polypore International Inc. (PPO) and Sumitomo Chemical Co., Ltd. reported that they have entered into a Settlement and License Agreement which ends all outstanding worldwide litigation between the two companies related to PPO's intellectual property rights on battery separator coating. Under the License Agreement, Sumitomo Chemical has licensed PPO's intellectual property related to coating separators for lithium-ion batteries. The financial terms of the Agreement include an up-front payment to PPO as well as recurring royalties. Shares of PPO climbed slightly $0.43 (or +1.14%) to $38.01 on Friday's market activity. PPO is a global high technology filtration company specializing in microporous membranes. PPO's flat sheet and hollow fiber membranes are used in specialized applications that require the removal or separation of various materials from liquids, primarily in the ultrafiltration and microfiltration markets. More about Polypore International Inc. (PPO) at www.polypore.net. ** Crown Equity Holdings Inc. (CRWE) is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, is targeting the multi-billion dollar social networking service market. Social networking services are changing the ways in which people use and engage with the Internet and with each other. A social networking service is an online service provided to the public for social interaction between families, friends, and also for gaining new friends over the internet. Social networking has expanded into other areas as well, introducing mobile access via smartphones, offering the same accessibility and interaction that users get when using their computer. CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States. CRWE‘s business plan is based on selling advertising to local businesses. Its goal is to facilitate exchanges of goods and services in a manner similar to Craigslist, a classified advertisements website with sections devoted to jobs, housing, personals, for sale, items wanted, services, community, gigs, résumés, and discussion forums. On Friday’s trading session, CRWE stock jumped $0.001 (or +20.00%) to $0.006 per share. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher. More about Crown Equity Holdings Inc. (CRWE) at www.crownequityhol dings.com. ** Read Full Disclaimer at www.drstockpick.co m/disclaimer  (Dec 28, 2013 | post #1)

Phoenix, AZ

Idenix (IDIX) Patent Infringement Lawsuit Against Gilead

Idenix Pharmaceuticals, Inc. (IDIX) recently reported that it has filed two lawsuits against Gilead: a patent infringement lawsuit in the U.S. District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the U.S. District Court in Wilmington, Delaware ** Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar social networking service market with its CRWE Network (CRWE-PR) project. Community of Encinitas, CA, visit CRWE Network Encinitas at http://encinitas.c rwe-pr.com. ** Progenics Pharmaceuticals, Inc. (PGNX) reported that findings from a Phase I study of its Imaging Agent, 1404, were presented at the meeting of the Society for Urologic Oncology in Rockville, Maryland. In this Phase I trial, according to PGNX, its imaging agent identified primary prostate cancer with a high degree of accuracy and, in addition, may have the ability to discriminate high grade prostate cancer from moderate and low grade disease. PGNX believes this is the kind of information men suffering from prostate cancer and their doctors need in order to best manage their disease. Full article on Mike Zaman website at http://mikezaman.c om/27235/stocks/id enix-idix-patent-i nfringement-lawsui t-against-gilead-p rogenics-pgnx-topl ine-data-from-stud y/  (Dec 8, 2013 | post #1)

Miami, FL

All the radars on Auxilium (AUXL)

Make sura that Auxilium (AUXL) is on your radar. Check this out: Shares of Auxilium Pharmaceuticals, Inc. (AUXL) soared after the company reported that the U.S. FDA has approved XIAFLEX(R) (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease, a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the male genital The treatment will cost nearly $20,000 per patient, per year. Each injection of Xiaflex costs $3,300. ** ZIOPHARM Oncology, Inc. (ZIOP) reported positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma ** Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, Crown Equity Holdings Inc. (CRWE) is targeting the multi-billion dollar social networking community service market with its CRWE Network (CRWE-PR) project. CRWE is currently developing a social networking service and phone app, CRWE Network (CRWE-PR), that is designed to target all the communities in every state of the United States. Community of Encinitas, CA, visit CRWE Network Encinitas at http://encinitas.c rwe-pr.com Read full article at http://drstockpick .com/26673/stock-a lerts/ziopharm-zio p-positive-data-au xilium-auxl-fda-gr een-light-for-3300 -painful-curvature -injection/  (Dec 8, 2013 | post #1)

Alexandria, VA

Keep a close eye on Ariad Pharmaceuticals (ARIA)

Keep a close eye on Ariad Pharmaceuticals (ARIA). Check this out: Shares of Ariad Pharmaceuticals Inc. (ARIA) soared $1.35 (or +35.74%) to $5.13 on Monday's market activity. Last week, ARIA reported adoption of a positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency on the continued availability of Iclusig(R) (ponatinib) in the EU for use in patients with leukaemias in its authorized indications with extra safety precautions to safeguard patients against an increased risk of occlusive vascular events. ** Looking to deliver value for its stockholders in both the near and long term, Crown Equity Holdings Inc. (CRWE) is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online b2b market, with its ts iB2B Global project. ** The price of Cubist Pharmaceuticals Inc. (CBST) stock jumped $5.26 (or +8.03%) to $70.76 after the company reported positive top-line results from pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazoba ctam in complicated urinary tract infections. CBST's ceftolozane/tazoba ctam, an antibiotic candidate being developed to treat certain Gram-negative infections, met its primary endpoint of statistical non-inferiority compared to levofloxacin (10% non-inferiority margin) Full article at http://drstockpick .com/26645/stock-a lerts/cubist-cbst- and-ariad-aria-epi demic-upward-path- on-trading-session /  (Nov 25, 2013 | post #1)